Welcome to our dedicated page for Novartis SEC filings (Ticker: NVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Novartis finances billion-dollar oncology trials, protects patents on blockbuster therapies, and manages global compliance can feel overwhelming. Even a Novartis annual report 10-K simplified still runs hundreds of pages, and a single Novartis quarterly earnings report 10-Q filing may hide crucial data on Kisqali sales or radioligand production capacity. When material events strike—such as an FDA letter or trial halt—a Novartis 8-K material events explained becomes mission-critical. Professionals need clarity fast.
Stock Titan delivers that clarity with Novartis SEC filings explained simply through AI-powered summaries that translate dense disclosures into plain English. Our platform provides understanding Novartis SEC documents with AI: revenue by therapeutic area, R&D outlays for rare-disease pipelines, and ongoing litigation updates appear instantly. Receive Novartis Form 4 insider transactions real-time and drill into Novartis executive stock transactions Form 4 to monitor buying or selling ahead of patent expiries. Expert commentary, real-time EDGAR feeds, and complete historical archives ensure nothing is missed.
Whether you are asking “What does Novartis report in their SEC filings?” or preparing a valuation model, this page has every document in one place. Set alerts for Novartis insider trading Form 4 transactions, compare divisions with Novartis earnings report filing analysis, or locate Novartis proxy statement executive compensation in seconds. From 10-K risk factors on biosimilar competition to footnote-level details on clinical milestones, Stock Titan equips investors, analysts, and pharmaceutical partners with the insights they need—quickly, clearly, and confidently.
Novartis’ tender offer for Tourmaline Bio advances as its subsidiary Torino Merger Sub updates terms and regulatory status. The offer seeks to purchase all outstanding shares of Tourmaline Bio at $48.00 per share in cash, without interest and subject to applicable withholding taxes, on the terms set out in the Offer to Purchase and Letter of Transmittal.
Novartis and Tourmaline filed their Premerger Notification and Report Forms on October 6, 2025, and the HSR Act waiting period expired on October 21, 2025 at 11:59 p.m. ET, satisfying the antitrust condition to the offer. The offer remains subject to the other conditions described in Section 15 — Conditions to the Offer. An exhibit was added for a Novartis press release dated October 22, 2025.
Novartis announced FDA approval of Rhapsido (regibrutinib) as the first oral Brutons tyrosine kinase inhibitor (BTKi) for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Rhapsido is taken twice daily, requires no injections or laboratory monitoring, and demonstrated onset of well-controlled disease (UAS7 ) as early as Week 2 and at Week 12, with about one-third of patients achieving complete absence of itch and hives at Week 12.
The prescribing information reports a safety profile that does not require lab monitoring; the most common adverse events (>=3%) were nasal congestion, nasopharyngitis, bleeding, headache, nausea, and abdominal pain. Novartis notes remibrutinib is also in development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa.
Novartis announced positive top-line results from two global Phase III trials (NEPTUNUS-1 and NEPTUNUS-2) of ianalumab in adults with active Sjögren's disease. Both trials met the primary endpoint, demonstrating statistically significant improvements in systemic disease activity measured by reduction in ESSDAI versus placebo.
NEPTUNUS-1 enrolled 275 patients and NEPTUNUS-2 enrolled 504, evaluating ianalumab 300 mg subcutaneous monthly or every three months versus placebo for up to 52 weeks. Novartis reported ianalumab was well tolerated with a favorable safety profile, described the medicine as having dual B cell-directed activity, and said it plans to present the data and submit to health authorities globally. The program has FDA Fast Track designation, and the release notes there is no guarantee of approval or commercial success.
FAQ
What is the current stock price of Novartis (NVS)?
What is the market cap of Novartis (NVS)?
